Weekly CEO News from Richard Ingram
October 1, 2015

At first glance it may seem gratuitous to discuss China and other autocratically-run emerging markets with a headline drawn from a movie which had nothing to do with China, and almost nothing to do with LA’s Chinatown. But in fact

Read more

Podcast: Play in new window | Play in new window (Duration: 13:16 — 6.1MB) DOW – 12 = 16,272 SPX + 3 = 1923 NAS + 6 = 4627 10 YR YLD – .02 = 2.04% OIL – .11 = 44.98 GOLD – 1.80

Read more

Nonfarm Payroll Friday Today is the Nonfarm Payroll announcement, and as a result you can expect a lot of noise in the marketplace. With that being the case, all trading opportunities will more than likely be of the shorter-term variety,

Read more

“I am amazed at how blatant a price manipulation algo is in gold futures this morning. Really affecting prices.” Eric Hunsader, Nanex Surprised?  Not so much. They do it almost every day. Speaking of another day, there is another fine for

Read more

Today I used Barchart to sort the NASDAQ 100 Index stock for those having both a technical buy signal of 80% or better and also a Weighted Alpha of 50.00+. Today only one made the list; Activision Blizzard (NASDAQ:ATVI) and another one

Read more

Markets are getting restless. Valuations are stretched, the global economy is shaky, and after six years of a bull market investors are taking every excuse to sell. Now, more than ever, it’s important to own quality businesses at fair valuations.

Read more

Back in June, we noted that a group of investors which included hedge funds, pension funds, university endowments, and others were looking to push forward with a lawsuit that alleged Wall Street had conspired to limit competition in the CDS

Read more

October 1, 2015

Minor Gains

Written by Posted in Finance Comments 0

Things were looking a lot brighter in premarket, but in the end bulls were able to push markets into a higher close, even if volume was lighter than yesterday. The S&P nicks a breakout of declining resistance from the September

Read more

Shares of Sarepta Therapeutics (SRPT) closed the day up 22.43% after announcing additional positive phase 2b data for its Duchenne Muscular Dystrophy drug. The company stated that their drug Eteplirsen allowed patients to gain an advantage of 151 meters in

Read more

Markets experienced another difficult month, weighed down by the familiar concerns surrounding China, oil prices and soft domestic economic data. A series of dismal economic reports came out of China spooking investors. Meanwhile, oil prices continued their downward slide despite

Read more